Peptides DB
Research-centric peptide and protocol reference hub

AOD-9604 vs Semaglutide

Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team

AOD-9604: Research use — not FDA-approvedSemaglutide: FDA-approved

A data-driven comparison of AOD-9604 and Semaglutide (also searched as Semaglutide vs AOD-9604) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

AOD-9604 centers on skin, while Semaglutide leans toward metabolic. On indexed research, Semaglutide is ahead (AOD-9604: 12 studies, Human evidence; Semaglutide: 60, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • •AOD-9604 is strongest for skin; Semaglutide for metabolic.
  • •Evidence: AOD-9604 Human evidence (12 studies) vs Semaglutide Human clinical (60).
  • •Check the FDA-approval status chips above before assuming a legal use pathway.

Effect profiles, overlaid

AOD-9604Semaglutide

At a glance

AOD-9604Human evidence

Lipolysis | Fat loss

Strongest: SkinStudies: 12Level: Limited Research
SemaglutideHuman clinical

GLP-1 receptor agonist | Type 2 diabetes management

Strongest: MetabolicStudies: 60Level: FDA Approved

AOD-9604 vs Semaglutide: side-by-side

MetricAOD-9604Semaglutide
ClassMetabolicMetabolic
Regulatory statusResearch use onlyFDA-approved
Evidence gradeHuman evidenceHuman clinical
Studies indexed1260
Research levelLimited ResearchFDA Approved
Strongest effectSkin & aestheticsMetabolic & appetite
Healing & recovery2.0▲2.0▲
Muscle & body comp1.0▲1.0▲
Metabolic & appetite3.05.0▲
Neuro & mood0.02.0▲
Sleep & circadian0.01.0▲
Inflammation & immune1.02.0▲
Skin & aesthetics3.0▲3.0▲

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertyAOD-9604Semaglutide
MechanismModified hGH fragment (176–191)GLP-1 receptor agonist
RouteSubcutaneous injection (research use)Subcutaneous injection (oral form also available)
Half-life—~7 days (≈165 h)
Time to peak—1–3 days
Duration of action—Weekly dosing

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is AOD-9604?

A GH-fragment–derived peptide primarily discussed for fat loss and body-composition change, sometimes with cartilage and joint-repair context.

Full AOD-9604 profile, mechanism & studies →

What is Semaglutide?

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone involved in glucose metabolism and appetite regulation. As a GLP-1 receptor agonist, semaglutide enhances insulin secretion in response to elevated blood glucose levels, suppresses glucagon secretion, and slows gastric emptying. These mechanisms contribute to improved glycemic control and increased satiety, making semaglutide a significant option in managing type 2 diabetes and obesity.

Full Semaglutide profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingEvenBoth ~2.0/5
MuscleEvenBoth ~1.0/5
MetabolicSemaglutide5.0/5 effect signal
NeuroSemaglutide2.0/5 effect signal
SleepSemaglutide1.0/5 effect signal
InflammationSemaglutide2.0/5 effect signal
SkinEvenBoth ~3.0/5

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack AOD-9604 and Semaglutide?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

AOD-9604 vs Semaglutide: side effects

AOD-9604

No community-reported effects logged yet.

Semaglutide

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

AOD-9604 has 12 approved studies indexed (Human evidence), and Semaglutide has 60 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is AOD-9604 or Semaglutide better?

It depends on your goal. AOD-9604 is strongest for skin; Semaglutide for metabolic. Semaglutide has more indexed studies (60). See the goal-by-goal breakdown above.

Is AOD-9604 or Semaglutide better for weight loss?

Semaglutide shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.

Is AOD-9604 or Semaglutide better for muscle?

Both land close on the muscle & body-composition axis.

Which has more research, AOD-9604 or Semaglutide?

AOD-9604 has 12 approved studies indexed (Human evidence); Semaglutide has 60 (Human clinical). Higher counts mean more to read, not proven superiority.

Can you stack AOD-9604 and Semaglutide?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of AOD-9604 vs Semaglutide?

AOD-9604: no community-reported effects logged yet. Semaglutide: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is AOD-9604 or Semaglutide FDA-approved?

AOD-9604 is a research-use compound and is not FDA-approved. Semaglutide is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Semaglutide better than AOD-9604?

For metabolic, Semaglutide has the edge; for skin, AOD-9604 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.